-
-
Patients with unexplained chronic fatigue and bodily pain are more likely to have rhinosinusitis symptoms than are people in the general population.
-
Eighty-seven percent or more of patients with fatal or nonfatal myocardial infarction have major risk factors prior to the event.
-
Azithromycin is an effective, single-drug therapy for mild-to-moderate community-acquired pneumonia.
-
Warren and colleagues performed a nonrandomized pre- and postobservational trial of an educational intervention to prevent catheter-associated bloodstream infections (CABSIs) in a 500-bed private community hospital in Missouri.
-
To determine practices regarding use of closed-system suctioning (CSS) and airway management of intubated patients, Sole and colleagues surveyed a national sample of 1665 registered nurses (RNs) and respiratory therapists (RTs) in 27 institutions.
-
A wide variety of therapeutic interventions have failed to produce a significant change in the mortality of critically ill patients. Studies of these interventions include numerous trials of anti-inflammatory agents in sepsis, the trial involving growth hormone in critically ill patients, as well as a host of other investigations.
-
The ARDSNetwork trial that began in 1996 (ARMA trial)1 was designed to test the validity of using lower tidal volumes in mechanical ventilators was halted because critics who were not a part of the ARDSNetwork argued that the control arm chosen was harmful and unethical.
-
Specialty beds marketed for ICU patients range from simple air-filled mattresses designed for use on ordinary hospital beds to high-tech, electronically controlled rotating or vibrating devices.
-
The FDA has approved vardenafil (LevitraBayer and GlaxoSmithKline) for the treatment of erectile dysfunction in men. Vardenafil joins sildenafil (Viagra) as the only 2 drugs approved for this indication in this country.
